Patent US4665094A successfully refreshed from Google Patents.
US4665094A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Oculoselective beta-blockers for treatment of elevated intraocular pressure
Assignee: Merck and Co Inc
•
Filing: 1985-08-29
•
Granted: 1987-05-12
•
Expires: 2005-08-29
Abstract
Abstract Hydroxyalkyl-phenoxy-propan-2-olamines and novel esters thereof are oculoselective beta -blockers useful in the treatment of elevated intraocular pressure with little or no effect on the pulmonary or cardiovascular system.
Inventors
- 👤 John J. Baldwin
- 👤 Gerald S. Ponticello
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-06 15:08
CPC Classifications
C; C07; C07C; C07C217/00; C07C217/02; C07C217/04; A; A61; A61K; A61K31/00; A61K31/21; A61K31/215; A61K31/22; A61K31/13; A61K31/135; A61P; A61P25/00; A61P25/02; A61P27/00; A61P27/02; A61P27/06; C07C217/06; C07C217/14
Claims Analysis
Total Claims: 9
Claim 1
Independent Claim
16 words
The compound (R)- or (S)-2-(4-(3-((1,1-dimethylethyl)amino)-2-hydroxypropoxy) phenyl)-ethyl acetate, [2-(4-(3-((1,1-dimethylethyl)amino) 2-hydroxypropoxy)phenyl)ethyl 2,2-dimethylacetate] or an ophthalmologically acceptable salt thereof.
Claim 2
Dependent Claim
16 words
The compound (R)- or (S)-2-(4-(3-((1,1-dimethylethyl)amino)-2-hydroxypropoxy) phenyl)-ethyl acetate, [2-(4-(3-((1,1-dimethylethyl)amino) 2-hydroxypropoxy)phenyl)ethyl 2,2-dimethylacetate] or an ophthalmologically acceptable salt thereof.
Claim 3
Dependent Claim
11 words
The (S)-enantiomer of claim 1 or an ophthalmologically acceptable salt thereof.
Claim 4
Independent Claim
45 words
A method of treating elevated intraocular pressure in a patient in need of such treatment which comprises the topical ocular administration of an effective intraocular pressure lowering amount of the compound (R)- or (S)-2-(4-(3-((1, 1-dimethylethyl)amino)-2-hydroxypropoxy)phenyl)ethyl acetate, [2-(4-(3-((1,1-dimethylethyl)amino)-2-hydroxypropoxy) phenyl)ethyl 2,2-dimethylacetate] or an ophthalmologically acceptable salt thereof.
Claim 5
Independent Claim
45 words
A method of treating elevated intraocular pressure in a patient in need of such treatment which comprises the topical ocular administration of an effective intraocular pressure lowering amount of the compound (R)- or (S)-2-(4-(3-((1, 1-dimethylethyl)amino)-2-hydroxypropoxy)phenyl)ethyl acetate, [2-(4-(3-((1,1-dimethylethyl)amino)-2-hydroxypropoxy) phenyl)ethyl 2,2-dimethylacetate] or an ophthalmologically acceptable salt thereof.
Claim 6
Dependent Claim
11 words
The method of claim 3, wherein the compound is the (S)-enantiomer.
Claim 7
Dependent Claim
38 words
An ophthalmic formulation for the topical ocular treatment of elevated intraocular pressure comprising an ophthalmologically acceptable carrier and an effective amount of the compound (R)- or (S)-2-(4-(3-((1,1-dimethylethyl)amino)-2-hydroxypropoxy) phenyl)ethyl acetate[; 2-(4-(3-((1,1-dimethylaethyl)amino)2-hydroxy-propoxy) phenyl)ethyl 2,2-dimethylacetate] or an ophthalmologically acceptable salt thereof.
Claim 8
Dependent Claim
38 words
An ophthalmic formulation for the topical ocular treatment of elevated intraocular pressure comprising an ophthalmologically acceptable carrier and an effective amount of the compound (R)- or (S)-2-(4-(3-((1,1-dimethylethyl)amino)-2-hydroxypropoxy) phenyl)ethyl acetate[; 2-(4-(3-((1,1-dimethylaethyl)amino)2-hydroxy-propoxy) phenyl)ethyl 2,2-dimethylacetate] or an ophthalmologically acceptable salt thereof.
Claim 9
Dependent Claim
25 words
The formulationo of claim 2 wherein the compound is the (S)-enantiomer of 2-(4-(3-((1,1-dimethyl-ethyl) amino)-2-hydroxypropoxy)phenyl)ethyl acetate[; [2-(4-(3-((1,1-dimethylethyl)amino)-2-hydroxypropoxy)phenyl) ethyl acetate 2,2-dimethylacetate] or an ophthalmologically acceptable salt thereof.
References Cited (Backward Citations)
US3542872A
Cited
US3872147A
Cited
GB1260848A
Cited
US3644469A
Cited
US3663607A
Cited
DE1966513A1
Cited
US3892799A
Cited
JPS4911847A
Cited
US3930016A
Cited
US4066768A
Cited
BE833291A
Cited
US4171370A
Cited
EP0041295A1
Cited
US4515814A
Cited
EP0082461A2
Cited
US4450172A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1990-05-11 | 1990-11-10 | 1991-05-12 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1994-05-11 | 1994-11-10 | 1995-05-12 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1998-05-11 | 1998-11-10 | 1999-05-12 | $7700.00 | Window Closed / Lapsed |